LifeSciences BC > News > Member Announcements > Page 2

Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (TNBC)

September 18, 2018
PhoenixMD

PMD-026, the first RSK inhibitor to demonstrate potential disease-modifying properties in TNBC, is now fully funded through IND- VANCOUVER, British Columbia and SAN DIEGO, Sept. 18, 2018 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the completion of a $2.7M financing effort, which includes … Continue reading Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (TNBC)

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

September 18, 2018
Aspect Biosystems Ltd.

September 18, 2018 09:00 AM Eastern Daylight Time VANCOUVER, British Columbia–(BUSINESS WIRE)–Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ … Continue reading Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares

September 17, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the closing of its previously announced public offering of 4,500,000 common shares pursuant to its existing shelf registration statement at a public offering price of $14.00 per share. The gross proceeds to Xenon from the … Continue reading Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares

Anti-migraine Head Patch – HeadaTerm – Receives FDA Clearance

September 17, 2018
WAT Medical Inc.

September 16th, 2018, Vancouver, BC – WAT Medical’s innovative technology to treat all primary headache, HeadaTerm, received its FDA clearance in September, 2018. This product, already approved by CE, HC, and now FDA, has been distributed in over 20 countries around the world. It has now officially entered the U.S. market as an effective treatment for … Continue reading Anti-migraine Head Patch – HeadaTerm – Receives FDA Clearance

Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares

September 13, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,500,000 common shares pursuant to its existing shelf registration statement at a public offering price of $14.00 per share. The gross proceeds to Xenon from the offering, … Continue reading Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares

World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions

September 13, 2018
The Centre for Drug Research and Development

Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians Declared a Global Health Priority by the World Health Organization in 2017 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment … Continue reading World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions

Canadian, US business leaders announce joint framework for cross-border growth

September 13, 2018
Cascadia Innovation Corridor Initiative

Canadian, US business leaders announce joint framework for cross-border growth Cascadia Innovation Corridor leadership builds capacity for innovation, economic opportunity VANCOUVER, BC – September 13, 2018 – Today, the Cascadia Innovation Corridor announced the formation of a binational steering committee composed of the region’s top business, research and community leaders. The Committee marks a step forward … Continue reading Canadian, US business leaders announce joint framework for cross-border growth

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

September 12, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a … Continue reading Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

GenXys Health Care Systems Raises $1.5 Million Seed Round to Launch Leading Precision Prescribing Software in the US Market

September 12, 2018
GenXys

Vancouver, Canada September 11th, 2018 – GenXys, a precision prescribing software company tackling a $130 billion global problem, is pleased to announce that it has secured $1.5 million in seed funding following early commercial success in Canada. This supports GenXys plans to expand into new regions to increase patient safety, medication effectiveness whilst reducing healthcare … Continue reading GenXys Health Care Systems Raises $1.5 Million Seed Round to Launch Leading Precision Prescribing Software in the US Market

Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program

September 10, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Sept. 10, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced it has signed an agreement with Valeant Pharmaceuticals Luxembourg S.a.r.l. and Valeant Pharmaceuticals Ireland Limited, indirect subsidiaries of Bausch Health Companies Inc., (together, Bausch Health) to buy out all milestone payments and royalties with respect to XEN1101, which is a Kv7 … Continue reading Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program